GlucoTrack Inc
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the… Read more
GlucoTrack Inc (GCTK) - Total Liabilities
Latest total liabilities as of September 2025: $5.54 Million USD
Based on the latest financial reports, GlucoTrack Inc (GCTK) has total liabilities worth $5.54 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GlucoTrack Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how GlucoTrack Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GlucoTrack Inc Competitors by Total Liabilities
The table below lists competitors of GlucoTrack Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AMEREN - Dusseldorf Stock Exchang
DU:AE4
|
Germany | €31.34 Billion |
|
PULTEGROUP - Dusseldorf Stock Exchang
DU:PU7
|
Germany | €5.39 Billion |
|
Gulf & Pacific Equities Corp
V:GUF
|
Canada | CA$28.70 Million |
|
Anacomp Inc
PINK:ANMP
|
USA | $5.09 Million |
|
Total Helium Ltd
OTCQB:TTLHF
|
USA | $2.35 Million |
|
Axim Biotechnologies Inc
PINK:AXIM
|
USA | $13.65 Million |
|
AGILENT TECH (AG8.SG)
STU:AG8
|
Germany | €5.09 Billion |
|
Mlabs Systems Bhd
KLSE:0085
|
Malaysia | RM11.48 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down GlucoTrack Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GlucoTrack Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GlucoTrack Inc (2011–2024)
The table below shows the annual total liabilities of GlucoTrack Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $18.93 Million | +1008.43% |
| 2023-12-31 | $1.71 Million | +41.39% |
| 2022-12-31 | $1.21 Million | +8.83% |
| 2021-12-31 | $1.11 Million | -31.65% |
| 2020-12-31 | $1.62 Million | -35.25% |
| 2019-12-31 | $2.51 Million | -29.58% |
| 2018-12-31 | $3.56 Million | -80.48% |
| 2017-12-31 | $18.24 Million | +36.04% |
| 2016-12-31 | $13.41 Million | +47.31% |
| 2015-12-31 | $9.10 Million | -18.58% |
| 2014-12-31 | $11.18 Million | -19.10% |
| 2013-12-31 | $13.82 Million | +948.79% |
| 2012-12-31 | $1.32 Million | +8.51% |
| 2011-12-31 | $1.21 Million | -- |